Role of endothelin-1 in congestive gastropathy in portal hypertensive rats

Shinichiro Migoh, Makoto Hashizume, Kouji Tsugawa, Kazuo Tanoue, Keizo Sugimachi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: The aim of this study was to determine the role of endothelin (ET)-1 in portal hypertensive gastropathy (PHG) under portal hypertension, in order to investigate whether the ET(A/B) receptor inhibitor improves the permeability of gastric mucosal microvessels in PHG. Methods and Results: Portal hypertensive rats (PVL) and sham-operated rats (CTR) were prepared and then the concentration of plasma ET-1 was measured and the vasopressor response to ET-1 was compared between the two groups. The plasma ET-1 levels in PVL increased significantly compared with CTR; however, the vasopressor response to ET-1 in PVL decreased more than in CTR. Next, the portal venous pressure was measured in both CTR and PVL pretreated with or without a nitric oxide (NO) synthase inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), before the injection of ET-1. The portal venous pressure of PVL after receiving ET-1 and being pretreated with L-NAME significantly increased in comparison to the pressure of PVL treated with ET-1 alone (without L-NAME). Moreover, Evans-Blue was injected into each rat and the absorbancy of the gastric contents was measured. The absorbancy of Evans-Blue in PVL increased significantly compared with CTR; however, the absorbancy in PVL+ ET(A/B) receptor inhibitor (Ro47-0203) decreased significantly more than in PVL. Conclusions: This study showed that ET-1 is a potent vasoconstrictive substance that also has a transitory vasodilative response through NO induced by ET-1 in portal hypertension. In addition, it was found that the vascular permeability of the gastric mucosa increased in portal hypertension and that Ro47-0203 inhibited the hyper-permeability. Accordingly, ET-1 may, thus, play an important role in the development of PHG through NO induced by ET-1. Ro47- 0203 may, therefore, be a useful substance for improving PHG in portal hypertension. (C) 2000 Blackwell Science Asia Pty Ltd.

Original languageEnglish
Pages (from-to)142-147
Number of pages6
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume15
Issue number2
DOIs
Publication statusPublished - Jan 1 2000

Fingerprint

Endothelin-1
NG-Nitroarginine Methyl Ester
Portal Hypertension
Endothelin B Receptors
Portal Pressure
Endothelin A Receptors
Evans Blue
Permeability
Nitric Oxide
Gastrointestinal Contents
Capillary Permeability
Gastric Mucosa
Microvessels
Nitric Oxide Synthase
Stomach
Pressure

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Role of endothelin-1 in congestive gastropathy in portal hypertensive rats. / Migoh, Shinichiro; Hashizume, Makoto; Tsugawa, Kouji; Tanoue, Kazuo; Sugimachi, Keizo.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 15, No. 2, 01.01.2000, p. 142-147.

Research output: Contribution to journalArticle

Migoh, Shinichiro ; Hashizume, Makoto ; Tsugawa, Kouji ; Tanoue, Kazuo ; Sugimachi, Keizo. / Role of endothelin-1 in congestive gastropathy in portal hypertensive rats. In: Journal of Gastroenterology and Hepatology (Australia). 2000 ; Vol. 15, No. 2. pp. 142-147.
@article{cd0f773e3d1746e8987e062c11622881,
title = "Role of endothelin-1 in congestive gastropathy in portal hypertensive rats",
abstract = "Background: The aim of this study was to determine the role of endothelin (ET)-1 in portal hypertensive gastropathy (PHG) under portal hypertension, in order to investigate whether the ET(A/B) receptor inhibitor improves the permeability of gastric mucosal microvessels in PHG. Methods and Results: Portal hypertensive rats (PVL) and sham-operated rats (CTR) were prepared and then the concentration of plasma ET-1 was measured and the vasopressor response to ET-1 was compared between the two groups. The plasma ET-1 levels in PVL increased significantly compared with CTR; however, the vasopressor response to ET-1 in PVL decreased more than in CTR. Next, the portal venous pressure was measured in both CTR and PVL pretreated with or without a nitric oxide (NO) synthase inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), before the injection of ET-1. The portal venous pressure of PVL after receiving ET-1 and being pretreated with L-NAME significantly increased in comparison to the pressure of PVL treated with ET-1 alone (without L-NAME). Moreover, Evans-Blue was injected into each rat and the absorbancy of the gastric contents was measured. The absorbancy of Evans-Blue in PVL increased significantly compared with CTR; however, the absorbancy in PVL+ ET(A/B) receptor inhibitor (Ro47-0203) decreased significantly more than in PVL. Conclusions: This study showed that ET-1 is a potent vasoconstrictive substance that also has a transitory vasodilative response through NO induced by ET-1 in portal hypertension. In addition, it was found that the vascular permeability of the gastric mucosa increased in portal hypertension and that Ro47-0203 inhibited the hyper-permeability. Accordingly, ET-1 may, thus, play an important role in the development of PHG through NO induced by ET-1. Ro47- 0203 may, therefore, be a useful substance for improving PHG in portal hypertension. (C) 2000 Blackwell Science Asia Pty Ltd.",
author = "Shinichiro Migoh and Makoto Hashizume and Kouji Tsugawa and Kazuo Tanoue and Keizo Sugimachi",
year = "2000",
month = "1",
day = "1",
doi = "10.1046/j.1440-1746.2000.02061.x",
language = "English",
volume = "15",
pages = "142--147",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Role of endothelin-1 in congestive gastropathy in portal hypertensive rats

AU - Migoh, Shinichiro

AU - Hashizume, Makoto

AU - Tsugawa, Kouji

AU - Tanoue, Kazuo

AU - Sugimachi, Keizo

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Background: The aim of this study was to determine the role of endothelin (ET)-1 in portal hypertensive gastropathy (PHG) under portal hypertension, in order to investigate whether the ET(A/B) receptor inhibitor improves the permeability of gastric mucosal microvessels in PHG. Methods and Results: Portal hypertensive rats (PVL) and sham-operated rats (CTR) were prepared and then the concentration of plasma ET-1 was measured and the vasopressor response to ET-1 was compared between the two groups. The plasma ET-1 levels in PVL increased significantly compared with CTR; however, the vasopressor response to ET-1 in PVL decreased more than in CTR. Next, the portal venous pressure was measured in both CTR and PVL pretreated with or without a nitric oxide (NO) synthase inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), before the injection of ET-1. The portal venous pressure of PVL after receiving ET-1 and being pretreated with L-NAME significantly increased in comparison to the pressure of PVL treated with ET-1 alone (without L-NAME). Moreover, Evans-Blue was injected into each rat and the absorbancy of the gastric contents was measured. The absorbancy of Evans-Blue in PVL increased significantly compared with CTR; however, the absorbancy in PVL+ ET(A/B) receptor inhibitor (Ro47-0203) decreased significantly more than in PVL. Conclusions: This study showed that ET-1 is a potent vasoconstrictive substance that also has a transitory vasodilative response through NO induced by ET-1 in portal hypertension. In addition, it was found that the vascular permeability of the gastric mucosa increased in portal hypertension and that Ro47-0203 inhibited the hyper-permeability. Accordingly, ET-1 may, thus, play an important role in the development of PHG through NO induced by ET-1. Ro47- 0203 may, therefore, be a useful substance for improving PHG in portal hypertension. (C) 2000 Blackwell Science Asia Pty Ltd.

AB - Background: The aim of this study was to determine the role of endothelin (ET)-1 in portal hypertensive gastropathy (PHG) under portal hypertension, in order to investigate whether the ET(A/B) receptor inhibitor improves the permeability of gastric mucosal microvessels in PHG. Methods and Results: Portal hypertensive rats (PVL) and sham-operated rats (CTR) were prepared and then the concentration of plasma ET-1 was measured and the vasopressor response to ET-1 was compared between the two groups. The plasma ET-1 levels in PVL increased significantly compared with CTR; however, the vasopressor response to ET-1 in PVL decreased more than in CTR. Next, the portal venous pressure was measured in both CTR and PVL pretreated with or without a nitric oxide (NO) synthase inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), before the injection of ET-1. The portal venous pressure of PVL after receiving ET-1 and being pretreated with L-NAME significantly increased in comparison to the pressure of PVL treated with ET-1 alone (without L-NAME). Moreover, Evans-Blue was injected into each rat and the absorbancy of the gastric contents was measured. The absorbancy of Evans-Blue in PVL increased significantly compared with CTR; however, the absorbancy in PVL+ ET(A/B) receptor inhibitor (Ro47-0203) decreased significantly more than in PVL. Conclusions: This study showed that ET-1 is a potent vasoconstrictive substance that also has a transitory vasodilative response through NO induced by ET-1 in portal hypertension. In addition, it was found that the vascular permeability of the gastric mucosa increased in portal hypertension and that Ro47-0203 inhibited the hyper-permeability. Accordingly, ET-1 may, thus, play an important role in the development of PHG through NO induced by ET-1. Ro47- 0203 may, therefore, be a useful substance for improving PHG in portal hypertension. (C) 2000 Blackwell Science Asia Pty Ltd.

UR - http://www.scopus.com/inward/record.url?scp=0034026534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034026534&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1746.2000.02061.x

DO - 10.1046/j.1440-1746.2000.02061.x

M3 - Article

C2 - 10735537

AN - SCOPUS:0034026534

VL - 15

SP - 142

EP - 147

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 2

ER -